Back

Evaluating the role of protein O-GlcNAcylation in doxorubicin-induced cardiotoxicity

20 January 2025 (18:20 - 18:30)
Organised by: Logo
Seminar Presentation Part of: Young Investigator Award Poster Session Drugs, Drug Targets Delegate Premium access HFA Winter Research Meeting on Translational Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Michele Russo

Catholic University of Louvain, Brussels (Belgium)

11 More presentations in this session

Presentation thumbnail
Unveiling doxorubicin-induced cardiotoxicity: into the heart with single-cell resolution
Mr M. Mergiotti (Turin, IT)
Abstract Slides
Presentation thumbnail
Molecular insight by snRNA sequencing into early changes after intravenous immunoglobulin therapy leading to improved long-term outcome in dilated cardiomyopathy
Doctor F. Peisker (Maastricht, NL)
Abstract
Presentation thumbnail
Cell-type specific senolytic effects differentially influence cardiac responses to induced senescence
Doctor E. Lazzarini (Lugano, CH)
Abstract Slides
Presentation thumbnail
Exploring the metabolic adaptations in doxorubicin-induced cardiotoxicity
Doctor G. Guerra (Turin, IT)
Abstract Slides
Presentation thumbnail
NCOR1 regulates macrophage-driven inflammation in heart failure with preserved ejection fraction via the NLRP3-IL1b pathway: a translational study
Doctor E. Gorica (Zurich, CH)
Abstract Slides

Access the full session

Session thumbnail
Young Investigator Award Poster Session

The Event

Event poster

HFA Winter Research Meeting on Translational Heart Failure 2025

20 January 2025 18:20 CET
You may be interested in
thumbnail
Congress Session
Young Investigator Award (YIA) Basic Science
17 May 2025
thumbnail
Congress Presentation
Protein O-GlcNAcylation: the dark side of glucose in heart failure.
21 May 2022
thumbnail
Congress Presentation
Cardioprotective effects of the flavonoid quercetin against doxorubicin-Induced cardiotoxicity in H9c2 cardiomyoblasts
20 June 2025
thumbnail
Congress Presentation
Targeted cardiac inactivation of Guanylate binding protein 5 (GBP5) protects from cardiotoxicity after doxorubicin treatment
20 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources